PTO/SB/05 (03-01)

Please type a plus sign (+) inside this box

+ Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Attorney Docket No. **VPI/01-116 DIV US**

UTILITY
PATENT APPLICATION
TRANSMITTAL

Guy Bemis First Inventor

TRANSMITTAL	Title	Inhibitors of Src and LCK Protein Kinases	
(Only for new nonprovisional applications under 37 CFR 1.53(b))	Expre	ss Mail Label No. EV 317 172 175 US	
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application con	ntents.	ADDRESS TO: MS Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	
1.		7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. paper c. Statements verifying identity of above copies	
- Brief Summary of the Invention - Brief Description of the Drawings (if filed)		ACCOMPANYING APPLICATIONS PARTS	
- Detailed Description - Claim(s) - Abstract of the Disclosure 4. Drawing(s) (35 U.S.C. 113) [Total Sheets] 5. Oath or Declaration [Total Pages] - Abstract of the Disclosure a. Newly executed (original or copy) b. X Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed) i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. Application Data Sheet. See 37 CFR 1.76 18. If a CONTINUING APPLICATION, check appropriate box, and Data Sheet under 37 CFR 1.76: Continuation X Divisional Continuation Prior application information: Examiner	-in-part(0 akR.F	Rao Group / Art Unit: 1624	
For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.			
19. CORRESPONDENCE ADDRESS			
X Customer Number or Bar Code Label	2	or Correspondence address below	
Andrea L. C. Robidoux Vertex Pharmaceuticals Incorporated			
Address 130 Waverly Street			
City Cambridge State		Massachusetts Zip Code 02139-4242	
	ephone	(617) 444-6536 Fax (617) 444-6483	
Name (Print/Type) Andrea L. C. Robidoux Registration No. (Attorney/Agent) 47, 902			
Signature Date December 4 2003			

Attorney Docket No.: VPI/01-116 DIV US

Certificate Of Mailing Under 37 C.F.R. § 1.10

Express Mailing No. EV 317 172 175 US Date of Deposit: December 4, 2003

I hereby certify that the following documents:

- 1. Utility Patent Application Transmittal;
- 2. Specification: 111 pages, (Desc. 74 pgs., claims 36 pgs., Abstract 1 pg);
- 3. Copy of executed Declaration Power of Attorney document (4 pages);
- 4. Preliminary Amendment;
- 5. IDS Transmittal Letter (in duplicate);
- 6. PTO-1449 Form (in duplicate);
- 7. Express Mail Page (1 pg); and
- 8. This Return Postcard Receipt

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the MS Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Karen DiRocco
(type or printed name of person mailing document(s))
Kally Dikolo
(signature of person mailing document(s))